# Path Fertility / SpermQT

> SpermQT is a clinically validated epigenetic sperm quality test from Path Fertility that measures DNA methylation dysregulation across 1,200+ genes essential for sperm function. Up to 25% of men with a "Normal" standard semen analysis have sperm incapable of producing a healthy pregnancy without advanced intervention (IVF/ICSI) — SpermQT is designed to catch what semen analysis alone misses. A 2026 peer-reviewed, multi-clinic study in the Journal of Assisted Reproduction and Genetics (JARG) found that men with an "Abnormal" SpermQT result recorded zero pregnancies via IUI across 537 real-world couples at 10 U.S. fertility clinics.

## What SpermQT is

- SpermQT analyzes DNA methylation patterns across 1,200+ genes to assess sperm function — not just count, shape, and movement, which is all a standard semen analysis measures.
- Results are reported as Excellent, Normal, or Abnormal.
- SpermQT is a complement to standard semen analysis, not a replacement.
- SpermQT alone costs $385; the SpermQT + Semen Analysis bundle costs $499 (cash-pay rates; pricing may vary with insurance or employer fertility benefits).

## Who it's for

- Couples and men trying to conceive, particularly those with a "Normal" semen analysis who are still not pregnant, or who have had a failed IUI cycle.
- Fertility physicians (Reproductive Endocrinologists, Reproductive Urologists) deciding between IUI and IVF/ICSI for a couple.

## Key evidence

- [JARG 2026 real-world study](https://doi.org/10.1007/s10815-025-03791-0) — "Epigenetic sperm quality testing for predicting fertility treatment success: a real-world and multi-site analysis." Analyzed 537 couples across 10 U.S. fertility clinics; men with an Abnormal SpermQT result recorded zero IUI pregnancies in the dataset.
- [F&S Science 2023 study](https://www.fertstertscience.org/article/S2666-335X(23)00049-6/fulltext) — "Epigenetic determinants of reproductive potential augment the predictive ability of the semen analysis."
- [Frontiers in Genetics 2023 study](https://www.frontiersin.org/articles/10.3389/fgene.2023.1125967/full) — "Tissue-specific DNA methylation variability and its potential clinical value."

## Key pages

- [For Patients / FAQ](https://pathfertility.com/patients/)
- [For Providers](https://pathfertility.com/providers/)
- [How SpermQT Works (the science)](https://pathfertility.com/product/)
- [Order SpermQT / Pricing](https://pathfertility.com/product-comparison/)

## Company

Path Fertility is a brand of Inherent Biosciences, Inc., a molecular diagnostics company based in Salt Lake City, UT. Founded by Andy Olson (CEO & Co-Founder) and Kristin Brogaard, Ph.D. (Chief Scientific Officer & Co-Founder, co-author of the JARG 2026 study).